Last reviewed · How we verify

conventional migraine drug treatment

Birjand University of Medical Sciences · FDA-approved active Small molecule

Conventional migraine drugs work through multiple mechanisms including vasoconstriction, serotonin receptor modulation, and pain pathway inhibition to relieve acute migraine symptoms.

Conventional migraine drugs work through multiple mechanisms including vasoconstriction, serotonin receptor modulation, and pain pathway inhibition to relieve acute migraine symptoms. Used for Acute migraine with or without aura, Migraine prophylaxis (for certain agents).

At a glance

Generic nameconventional migraine drug treatment
SponsorBirjand University of Medical Sciences
Drug classTriptan, ergot alkaloid, or NSAID (class varies by specific agent)
Target5-HT1B/1D receptors (triptans); COX inhibition (NSAIDs); or alpha-adrenergic/serotonergic receptors (ergots)
ModalitySmall molecule
Therapeutic areaNeurology
PhaseFDA-approved

Mechanism of action

Conventional migraine treatments typically include triptans (5-HT1B/1D receptor agonists causing cranial vasoconstriction), ergot alkaloids, and NSAIDs that reduce inflammation and pain signaling. These agents target the trigeminal system and cerebral blood vessels to abort migraine attacks or prevent their progression. The specific mechanism depends on the drug class used, ranging from direct vasoconstrictive effects to modulation of neuropeptide release.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: